CRSP - CRISPRセラピュ―ティクス （CRISPR Therapeutics AG） CRISPRセラピュ―ティクスCRSPのチャート
CRSPの企業情報
| symbol | CRSP |
|---|---|
| 会社名 | CRISPR Therapeutics AG （CRISPRセラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA) which is comprised of a crRNA component and a tracrRNA component either individually or combined together as a single guide RNA. The Company has business operations in London the United Kingdom as well as research and development operations in Cambridge the United States. CRISPRセラピュ―ティクスはスイスのバイオ医薬品企業。ゲノム編集に従事し、遺伝子ベ―スの病気の治療に使用される「CRISPR/Cas9」プラットフォ―ムを開発する。スイス、米国、英国で事業を展開する。「CRISPR」ベ―スの開発をバイエルとバ―テックス・ファ―マシュ―ティカルズと協業する。本社はバ―ゼル。 CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland. |
| 本社所在地 | Baarerstrasse 14 Zug 6300 CHE |
| 代表者氏名 | Rodger Novak ロジャーノヴァク |
| 代表者役職名 | Chairman of the Board of Directors President Founder |
| 電話番号 | +41 41-561-3277 |
| 設立年月日 | 41548 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2016年 |
| 従業員数 | 127人 |
| url | www.crisprtx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/crsp |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -83.54900 |
| 終値（lastsale） | 36.6 |
| 時価総額（marketcap） | 1732197333.6 |
| 時価総額 | 時価総額（百万ドル） 1894.215 |
| 売上高 | 売上高（百万ドル） 37.15800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1574.478 |
| 当期純利益 | 当期純利益（百万ドル） -84.94600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Crispr Therapeutics AG revenues decreased 61% to $2.4M. Net loss increased 52% to $66.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing increase of 31% to $37.1M (expense) Stock-based Compensation in R&D increase from $3.7M to $8.1M (expense). |
CRSPのテクニカル分析
CRSPのニュース
New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress 2020/05/14 13:02:06 GlobeNewswire
ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, May 14, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals…
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates 2020/04/28 23:45:05 Zacks Investment Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -5.50% and -97.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for 2020/04/27 16:31:48 Zacks Investment Research
CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes CRISPR Therapeutics AG (CRSP) a New Buy Stock 2020/04/27 16:00:06 Zacks Investment Research
CRISPR Therapeutics AG (CRSP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Les biotech helvétiques ont généré près de 5 milliards l’an dernier 2020/04/21 09:45:24 Allnews
La hausse a été alimentée par les revenus des collaborations conclues par AC Immune, Basilea et Crispr Therapeutics, ainsi que par l’accélération des revenus des produits déjà commercialisés.
CRISPR Therapeutics Proposes Changes to the Board of Directors | MarketScreener 2020/02/26 21:06:29 MarketScreener
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 26, 2020 -- CRISPR Therapeutics , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today… | February 26, 2020
CRISPR Therapeutics Proposes Changes to the Board of Directors 2020/02/26 21:05:00 GlobeNewswire
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on…
Global Forecast & Outlook for Crispr Technology, 2021-2026: North America, Europe, Asia-Pacific, Latin America, Africa & Middle East - ResearchAndMarkets.com 2020/02/14 17:31:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "2020 Global Forecast for Crispr Technology (2021-2026 Outlook)-High Tech & Emerging Markets Report" report has been added to ResearchAndMarkets.com's offering. The 2020 Global Forecast for Crispr Technology (2021-2026 Outlook)-High Tech & Emerging Markets Report, contains timely and accurate market statistics and forecasts on the market for over 140 countries. Estimates on equipment or material sales (product shipments value) are published historically for
Stock To Watch: CRISPR Therapeutics (CRSP) 2020/02/13 10:12:00 RTT News
CRISPR Therapeutics AG (CRSP), which is down more than 20% from its yearly high of $74, recorded last December, expects 2020 to have the potential to be a pivotal year in the company's growth.
CRISPR Therapeutics AG (CRSP) Beats Q4 Earnings and Revenue Estimates 2020/02/12 23:55:02 Zacks Investment Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 1175.00% and 3.42%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
The Chinese scientist who claims to have edited babies' DNA has been sentenced to 3 years in prison. Here's a timeline of the controversy. 2019/12/30 15:58:00 Business Insider
Chinese scientist He Jiankui, who claims to have made the first genetically edited babies in the world using CRISPR technology, has been sentenced to three years in prison. Many scientists, ethicists, and government officials have criticized He, calling his research unethical and dangerous. After presenting his findings at an international summit in November 2018, He vanished from public view until reports claimed he was being detained at a university guesthouse. On Monday, state media reported that He has been sentenced to three years in prison and faces a $430,000 fine. Two of his colleagues also face prison time. Visit Business Insider's homepage for more stories. In November 2018, a Chinese scientist claimed he had made the first genetically-edited babies in the world, causing sharp criticism from other scientists, ethicists, and government officials. The scientist, He Jiankui, used the gene-editing tool CRISPR-cas9, which is considered risky because it can inadvertently change a large portion of a person's DNA and have unintended consequences.
Chinese scientist who genetically edited babies will spend 3 years in prison 2019/12/30 14:26:48 BGR.com
One of the craziest stories to come out of 2018 was the saga of a Chinese scientist named He Jiankui. The genetics researcher took it upon himself to use the CRISPR gene-editing technique to modify human embryos and then have those embryos carried to term by their mothers. This resulted in what are believed to be the first genetically modified babies ever born. The work sparked immediate criticism from He's peers and the scientific community at large. Scientists around the globe condemned He's work and the Chinese government kept him under strict house arrest while it decided how to proceed. Now, over a year after the experiments were made public, He has received a prison sentence of three years . Three years in prison might sound like a big deal — and, to be fair, it's a significant sentence, especially in the realm of science — but it's a far cry from the punishment some feared He might face. Earlier this year, some of He's colleagues even thought he might face a death penalty for moving forward with his own human gene editing ambitions.
Global CRISPR Technology Market Report 2019-2025 with Analysis of Key Companies - Thermo Fisher Scientific, Merck KGaA, GenScript Biotech, Horizon Discovery Group, CRISPR Therapeutics - ResearchAndMarkets.com 2019/12/05 18:55:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Global CRISPR Technology Market 2019-2025" report has been added to ResearchAndMarkets.com's offering. The global CRISPR technology market is expected to witness a significant growth rate during the forecast period. CRISPR technology enables the alteration of DNA sequences and modifies the gene function. CRISPR technology can be used for various applications such as treatment of diseases, correcting gene, crop modification, bio-fuel manufacturing and many more. Ind
Swiss Health-care Concern out with Big Stock Offering 2019/11/20 19:01:38 Baystreet.ca
Crispr Therapeutics AG (NASDAQ:CRSP) saw its shares drop sharply Wednesday, after reporting a 4.25-million share common stock offering. The Swiss-based biopharmaceutical company, with offices in Cambridge, Mass., focuses on developing transformative …
The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data 2019/11/20 12:25:05 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan plc (NYSE: AGN )(announced publication of Phase 3 study results of migraine drug candidate) Agenus Inc (NASDAQ: AGEN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS )(announced a collaboration agreement with Idorsia Pharma for developing a drug-device combo for heart attack) Ardelyx Inc (NASDAQ: ARDX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) CNS Pharmaceuticals Inc (NASDAQ: CNSP )(IPOed Nov. 8) Crispr Therapeutics AG (NASDAQ: CRSP )( announced positive Phase 1/2 results for gene-editing investigational therapy) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Edwards Lifesciences Corp (NYSE: EW ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Galera Therapeutics Inc (NASDAQ: GRTX )(IPOed Nov.